Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-007981.pdf
0001179110-19-007981.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-007985.pdf
0001179110-19-007985.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-007986.pdf
0001179110-19-007986.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-007987.pdf
0001179110-19-007987.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-007889.pdf
0001179110-19-007889.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-007891.pdf
0001179110-19-007891.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-007893.pdf
0001179110-19-007893.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-007897.pdf
0001179110-19-007897.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-007896.pdf
0001179110-19-007896.rtf
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-19-005739.pdf
0001558370-19-005739.rtf
0001558370-19-005739.xls